- Home
- » Tags
- » Blinatumomab
Top View
- INN Working Document 05.179 Update 2011
- Consensus Statement on Immunotherapy for the Treatment of Multiple Myeloma
- Prophylaxis Guidelines for the Adult Hematology Patient
- Jco3615newview 1..1
- (INN) for Biological and Biotechnological Substances
- Cytokine Release Syndrome (CRS)
- Long-Term Follow-Up of Serum Immunoglobulin Levels in Blinatumomab-Treated Patients with Minimal Residual Disease-Positive B-Precursor Acute Lymphoblastic Leukemia
- The Many Facets of CD38 in Lymphoma: from Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
- 125557Orig1s000
- BLINCYTO (Blinatumomab) Is a Bispecific CD19-Directed CD3 T-Cell Engager That Binds to CD19 (Expressed on Cells of B-Lineage Origin) and CD3 (Expressed on T Cells)
- Medical Drug Prior Authorization List
- Blincyto, INN-Blinatumomab
- Cytokine Release Syndrome with the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment
- Acute Myeloid Leukemia (AML)
- Role of Blinatumomab in Acute Lymphoblastic Leukemia
- Pan-Canadian Pricing Alliance
- Advances in Llm
- Leukemia Insights Newsletter January 2020
- Supplementary File 1 (PDF, 469 Kib)
- Cardiotoxicity of Novel Targeted Hematological Therapies
- Blinatumomab: a Bispecific T Cell Engager (Bite) Antibody Against
- PMPRB Ceiling Price Proposed Guidelines – November 2019 Oncology Case Studies (2020-02-13 Ver1.1)
- Astellas Strategy
- Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens
- MD Anderson Cancer Center
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- AML Gemtuzumab Ozogamicin
- Oncology Medications Policy (1403)
- Blincyto, INN-Blinatumomab
- Oncology Therapy for the Generalist
- Proposed Additions to the NIOSH Hazardous Drug List 2018 Peer Review Comments
- Cost by Outcomes Analysis of Blinatumomab and Inotuzumab
- Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (ALL)
- Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
- Novel Treatments for Solid-Organ & Hematologic Malignancies
- The New Therapeutic Horizons for Acute Lymphoblastic Leukemia
- Game Changers in Pediatric Cancer Jane De Lartigue, Phd
- Extract from Clinical Evaluation Report Blinatumomab
- 17 FDA Priority Review Status for Defibrotide and Halaven
- And BRAF-Mutated Colorectal Cancer Cells
- Clinical Trial Update on Bispecific Antibodies, Antibody-Drug
- Blinatumomab, a Bispecific B-Cell and T-Cell Engaging Antibody, in the Treatment of B-Cell Malignancies
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- MEDICAL DRUGS PRIOR AUTHORIZATION LIST Effective 1/22/2021
- Blinatumomab for the Treatment of Philadelphia Chromosome–Negative, Precursor B-Cell
- Clinical Practice Guideline on Immunotherapy for the Treatment of Acute Leukemia
- Blinatumomab for Acute Lymphoblastic Leukemia
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Chicken Scfvs with an Artificial Cysteine for Site-Directed Conjugation
- New Drug Updates in Hematologic Malignancies Rebecca J
- Availability and Affordability of Drugs with a Conditional Approval by the European Medicines Agency; Comparison of Korea with Other Countries and the Implications
- Blincyto® (Blinatumomab) to Include Approval of Tafinlar® (Dabrafenib)
- A Retrospective Examination of the Us Food and Drug Administration's Clinical Pharmacology Reviews of Oncology Biologics for P
- Monoclonal Antibodies in Cancer Therapy
- All ETCTN Trials
- WO 2018/087126 Al 17 May 2018 (17.05.2018) W !P O PCT
- 761040Orig1s000
- Blinatumomab
- 5-Azacytidine Prevents Relapse and Produces Long-Term Complete Remissions in Leukemia Xenografts Treated with Moxetumomab Pasudo
- Download Article (PDF)
- Blincyto® (Blinatumomab)
- CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
- Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
- Recent Developments in Immunotherapy for Acute Lymphoblastic Leukemia
- NCCP Extravasation Classification of Systemic Anti-Cancer Therapy
- Blinatumomab Retreatment After Relapse in Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
- Redirected T Cell Engaging Therapeutics in Immuno-Oncology April 2020